Guidelines for the management of dermatomycosis (2019)

Guidelines Committee of the Japanese Dermatological Association

doi:10.1111/1346-8138.15618

Guidelines for the management of dermatomycosis (2019)

Guidelines Committee of the Japanese Dermatological Association

Reserch and Clinical Center for Yusho and Dioxin

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

The “Guidelines for the management of dermatomycosis” of the Japanese Dermatological Association were first published in Japanese in 2009 and the Guidelines Committee of the Japanese Dermatological Association revised it in 2019. The first guidelines was prepared according to the opinions of the Guidelines Committee members and it was of educational value. The revised version is composed of introductory descriptions of the disease concepts, diagnosis, medical mycology and recent advances in treatment, along with clinical questions (CQ), which is intended to help in general practice for dermatologists. The CQ are limited to those involved in therapy but include some of the recently launched antifungal agents. The level of evidence and the degree of recommendation for each item were reviewed by the committee based on clinical studies published by 2018. For rare dermatomycoses, recommendations by the committee are described in the guidelines. In this field, there are still few good quality studies on treatment. Periodic revision in line with new evidence is necessary.

Original language	English
Pages (from-to)	1343-1373
Number of pages	31
Journal	Journal of Dermatology
Volume	47
Issue number	12
DOIs	https://doi.org/10.1111/1346-8138.15618
Publication status	Published - Dec 2020

All Science Journal Classification (ASJC) codes

Dermatology

Access to Document

10.1111/1346-8138.15618

Cite this

@article{85d44e21c07e4e66a8d8856e99daf59b,

title = "Guidelines for the management of dermatomycosis (2019)",

abstract = "The “Guidelines for the management of dermatomycosis” of the Japanese Dermatological Association were first published in Japanese in 2009 and the Guidelines Committee of the Japanese Dermatological Association revised it in 2019. The first guidelines was prepared according to the opinions of the Guidelines Committee members and it was of educational value. The revised version is composed of introductory descriptions of the disease concepts, diagnosis, medical mycology and recent advances in treatment, along with clinical questions (CQ), which is intended to help in general practice for dermatologists. The CQ are limited to those involved in therapy but include some of the recently launched antifungal agents. The level of evidence and the degree of recommendation for each item were reviewed by the committee based on clinical studies published by 2018. For rare dermatomycoses, recommendations by the committee are described in the guidelines. In this field, there are still few good quality studies on treatment. Periodic revision in line with new evidence is necessary.",

author = "{Guidelines Committee of the Japanese Dermatological Association} and Takashi Mochizuki and Ryoji Tsuboi and Ken Iozumi and Sumiko Ishizaki and Tsuyoshi Ushigami and Yumi Ogawa and Takehiko Kaneko and Masaaki Kawai and Yuki Kitami and Masahiro Kusuhara and Takeshi Kono and Toshiki Sato and Tomotaka Sato and Harunari Shimoyama and Motoi Takenaka and Hiroshi Tanabe and Gaku Tsuji and Yuichiro Tsunemi and Yasuki Hata and Kazutoshi Harada and Tomoo Fukuda and Tetsuo Matsuda and Ryuji Maruyama",

note = "Funding Information: The present guidelines will be published on the Japanese Dermatological Association website and in the Japanese Journal of Dermatology. While referring to the GRADE classification, the criteria for evidence level classification and grades of recommendation used in the “Guidelines for the management of malignant skin tumors, second edition” from the Japanese Dermatological Association3 were adopted in the present guidelines and should be amended or updated at the next revision. Systematic review or meta-analysis One or more RCT Controlled study without randomization Analytical study (cohort study or case–control study) Descriptive study (case report or case series study) Opinions of an expert committee or individual expertise Strongly recommended (based on at least one level I or level II evidence of good quality) Recommended (based on at least one level II evidence showing one or more efficacies of poor quality, one level III evidence of good quality, or one level IV evidence of very good quality) May be recommended (based on level III to IV evidence of poor quality, several level V evidences of good quality, or level VI evidence approved by the committee) Not recommended owing to lack of evidence (no valid evidence or invalid evidence) Recommended not to use (good quality evidence demonstrating either harmful effect or no effect) It should be noted that some of the grades of recommendation in the text may not match the above criteria because they were decided upon by a consensus of the committee owing to insufficient international evidence for the pertinent items. Further, non-Japanese medical practice guidelines in these items were regarded as equivalent to an RCT. All the costs required for the preparation of the guidelines were paid by the Japanese Dermatological Association. The following declarations are made with regard to the drugs recommended or otherwise mentioned in the guidelines, in accordance with the policy of a 3-year limitation on conflicts of interest (COI) of the Japanese Dermatological Association: Y. Tsunemi received lecture fees from Eisai, Sato Pharmaceutical and Maruho. K. Harada received lecture fees from Sato Pharmaceutical. R. Maruyama received research funds from Sato Pharmaceutical. R. Tsuboi and K. Harada received a grant from Torii Pharmaceutical, Maruho, Kaken Pharmaceutical and Eisai. Y. Tsunemi received a grant from Maruho. There were no other COI requiring disclosure in the preparation of the present guidelines. If a committee member was involved in the development of a specific drug or its use or had any COI, he or she was strictly excluded from aspects of the work on the present guidelines involving the said drug. The preparation of the “Guidelines for the management of dermatomycosis (2019)” was a joint project undertaken by the Japanese Dermatological Association and the Japanese Society for Medical Mycology. The core members of the committee were chosen from the Japanese Society for Medical Mycology, who are also members of the Japanese Dermatological Association. Younger researchers were also added as committee members. The directors of both societies approved the committee members. The revision process began in June 2017 under the auspices of the Japanese Dermatological Association, which provided financial support, including expenses for travel and meetings. Each committee member was assigned the task of gathering evidence and discussing and preparing the draft of the guidelines. Finally, the draft was reviewed by representatives of the Japanese Dermatological Association (public comment). Dermatomycosis, including dermatophytosis, is commonly encountered in routine medical care. In Japan, 21.6% of the population are estimated to have tinea pedis, while 10.0% are estimated to have tinea unguium.1 Diagnosis and treatment of dermatomycosis are routine in dermatological practice. However, the number of dermatologists interested in basic and clinical research on dermatomycosis has recently been declining, and finding individuals with the requisite training and education in the diagnosis and treatment of this disease is becoming increasingly difficult. Against this background, the Japanese Dermatological Association released the “Guidelines for the management of dermatomycosis (2009)” in Japanese.2 The first edition was prepared according to the opinions of the guideline committee members. The present, revised version includes clinical questions (CQ), levels of evidence and grades of recommendation for each item (Table 1). In addition, the introductory descriptions of the disease and its diagnosis and treatment in the first edition were retained in summarized form in the current guidelines. CQ were prepared only for selected topics because the level of evidence for dermatomycosis is generally not high. A, strongly recommended; B, recommended; C1, may be recommended; C2, not recommended due to lack of evidence; D, recommended not to use. Funding Information: All the costs required for the preparation of the guidelines were paid by the Japanese Dermatological Association. The following declarations are made with regard to the drugs recommended or otherwise mentioned in the guidelines, in accordance with the policy of a 3‐year limitation on conflicts of interest (COI) of the Japanese Dermatological Association: Y. Tsunemi received lecture fees from Eisai, Sato Pharmaceutical and Maruho. K. Harada received lecture fees from Sato Pharmaceutical. R. Maruyama received research funds from Sato Pharmaceutical. R. Tsuboi and K. Harada received a grant from Torii Pharmaceutical, Maruho, Kaken Pharmaceutical and Eisai. Y. Tsunemi received a grant from Maruho. There were no other COI requiring disclosure in the preparation of the present guidelines. If a committee member was involved in the development of a specific drug or its use or had any COI, he or she was strictly excluded from aspects of the work on the present guidelines involving the said drug. Publisher Copyright: {\textcopyright} 2020 Japanese Dermatological Association",

year = "2020",

month = dec,

doi = "10.1111/1346-8138.15618",

language = "English",

volume = "47",

pages = "1343--1373",

journal = "Journal of Dermatology",

issn = "0385-2407",

publisher = "Wiley-Blackwell",

number = "12",

}

TY - JOUR

T1 - Guidelines for the management of dermatomycosis (2019)

AU - Guidelines Committee of the Japanese Dermatological Association

AU - Mochizuki, Takashi

AU - Tsuboi, Ryoji

AU - Iozumi, Ken

AU - Ishizaki, Sumiko

AU - Ushigami, Tsuyoshi

AU - Ogawa, Yumi

AU - Kaneko, Takehiko

AU - Kawai, Masaaki

AU - Kitami, Yuki

AU - Kusuhara, Masahiro

AU - Kono, Takeshi

AU - Sato, Toshiki

AU - Sato, Tomotaka

AU - Shimoyama, Harunari

AU - Takenaka, Motoi

AU - Tanabe, Hiroshi

AU - Tsuji, Gaku

AU - Tsunemi, Yuichiro

AU - Hata, Yasuki

AU - Harada, Kazutoshi

AU - Fukuda, Tomoo

AU - Matsuda, Tetsuo

AU - Maruyama, Ryuji

N1 - Funding Information: The present guidelines will be published on the Japanese Dermatological Association website and in the Japanese Journal of Dermatology. While referring to the GRADE classification, the criteria for evidence level classification and grades of recommendation used in the “Guidelines for the management of malignant skin tumors, second edition” from the Japanese Dermatological Association3 were adopted in the present guidelines and should be amended or updated at the next revision. Systematic review or meta-analysis One or more RCT Controlled study without randomization Analytical study (cohort study or case–control study) Descriptive study (case report or case series study) Opinions of an expert committee or individual expertise Strongly recommended (based on at least one level I or level II evidence of good quality) Recommended (based on at least one level II evidence showing one or more efficacies of poor quality, one level III evidence of good quality, or one level IV evidence of very good quality) May be recommended (based on level III to IV evidence of poor quality, several level V evidences of good quality, or level VI evidence approved by the committee) Not recommended owing to lack of evidence (no valid evidence or invalid evidence) Recommended not to use (good quality evidence demonstrating either harmful effect or no effect) It should be noted that some of the grades of recommendation in the text may not match the above criteria because they were decided upon by a consensus of the committee owing to insufficient international evidence for the pertinent items. Further, non-Japanese medical practice guidelines in these items were regarded as equivalent to an RCT. All the costs required for the preparation of the guidelines were paid by the Japanese Dermatological Association. The following declarations are made with regard to the drugs recommended or otherwise mentioned in the guidelines, in accordance with the policy of a 3-year limitation on conflicts of interest (COI) of the Japanese Dermatological Association: Y. Tsunemi received lecture fees from Eisai, Sato Pharmaceutical and Maruho. K. Harada received lecture fees from Sato Pharmaceutical. R. Maruyama received research funds from Sato Pharmaceutical. R. Tsuboi and K. Harada received a grant from Torii Pharmaceutical, Maruho, Kaken Pharmaceutical and Eisai. Y. Tsunemi received a grant from Maruho. There were no other COI requiring disclosure in the preparation of the present guidelines. If a committee member was involved in the development of a specific drug or its use or had any COI, he or she was strictly excluded from aspects of the work on the present guidelines involving the said drug. The preparation of the “Guidelines for the management of dermatomycosis (2019)” was a joint project undertaken by the Japanese Dermatological Association and the Japanese Society for Medical Mycology. The core members of the committee were chosen from the Japanese Society for Medical Mycology, who are also members of the Japanese Dermatological Association. Younger researchers were also added as committee members. The directors of both societies approved the committee members. The revision process began in June 2017 under the auspices of the Japanese Dermatological Association, which provided financial support, including expenses for travel and meetings. Each committee member was assigned the task of gathering evidence and discussing and preparing the draft of the guidelines. Finally, the draft was reviewed by representatives of the Japanese Dermatological Association (public comment). Dermatomycosis, including dermatophytosis, is commonly encountered in routine medical care. In Japan, 21.6% of the population are estimated to have tinea pedis, while 10.0% are estimated to have tinea unguium.1 Diagnosis and treatment of dermatomycosis are routine in dermatological practice. However, the number of dermatologists interested in basic and clinical research on dermatomycosis has recently been declining, and finding individuals with the requisite training and education in the diagnosis and treatment of this disease is becoming increasingly difficult. Against this background, the Japanese Dermatological Association released the “Guidelines for the management of dermatomycosis (2009)” in Japanese.2 The first edition was prepared according to the opinions of the guideline committee members. The present, revised version includes clinical questions (CQ), levels of evidence and grades of recommendation for each item (Table 1). In addition, the introductory descriptions of the disease and its diagnosis and treatment in the first edition were retained in summarized form in the current guidelines. CQ were prepared only for selected topics because the level of evidence for dermatomycosis is generally not high. A, strongly recommended; B, recommended; C1, may be recommended; C2, not recommended due to lack of evidence; D, recommended not to use. Funding Information: All the costs required for the preparation of the guidelines were paid by the Japanese Dermatological Association. The following declarations are made with regard to the drugs recommended or otherwise mentioned in the guidelines, in accordance with the policy of a 3‐year limitation on conflicts of interest (COI) of the Japanese Dermatological Association: Y. Tsunemi received lecture fees from Eisai, Sato Pharmaceutical and Maruho. K. Harada received lecture fees from Sato Pharmaceutical. R. Maruyama received research funds from Sato Pharmaceutical. R. Tsuboi and K. Harada received a grant from Torii Pharmaceutical, Maruho, Kaken Pharmaceutical and Eisai. Y. Tsunemi received a grant from Maruho. There were no other COI requiring disclosure in the preparation of the present guidelines. If a committee member was involved in the development of a specific drug or its use or had any COI, he or she was strictly excluded from aspects of the work on the present guidelines involving the said drug. Publisher Copyright: © 2020 Japanese Dermatological Association

PY - 2020/12

Y1 - 2020/12

N2 - The “Guidelines for the management of dermatomycosis” of the Japanese Dermatological Association were first published in Japanese in 2009 and the Guidelines Committee of the Japanese Dermatological Association revised it in 2019. The first guidelines was prepared according to the opinions of the Guidelines Committee members and it was of educational value. The revised version is composed of introductory descriptions of the disease concepts, diagnosis, medical mycology and recent advances in treatment, along with clinical questions (CQ), which is intended to help in general practice for dermatologists. The CQ are limited to those involved in therapy but include some of the recently launched antifungal agents. The level of evidence and the degree of recommendation for each item were reviewed by the committee based on clinical studies published by 2018. For rare dermatomycoses, recommendations by the committee are described in the guidelines. In this field, there are still few good quality studies on treatment. Periodic revision in line with new evidence is necessary.

AB - The “Guidelines for the management of dermatomycosis” of the Japanese Dermatological Association were first published in Japanese in 2009 and the Guidelines Committee of the Japanese Dermatological Association revised it in 2019. The first guidelines was prepared according to the opinions of the Guidelines Committee members and it was of educational value. The revised version is composed of introductory descriptions of the disease concepts, diagnosis, medical mycology and recent advances in treatment, along with clinical questions (CQ), which is intended to help in general practice for dermatologists. The CQ are limited to those involved in therapy but include some of the recently launched antifungal agents. The level of evidence and the degree of recommendation for each item were reviewed by the committee based on clinical studies published by 2018. For rare dermatomycoses, recommendations by the committee are described in the guidelines. In this field, there are still few good quality studies on treatment. Periodic revision in line with new evidence is necessary.

UR - http://www.scopus.com/inward/record.url?scp=85091861414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091861414&partnerID=8YFLogxK

U2 - 10.1111/1346-8138.15618

DO - 10.1111/1346-8138.15618

M3 - Article

C2 - 32978814

AN - SCOPUS:85091861414

SN - 0385-2407

VL - 47

SP - 1343

EP - 1373

JO - Journal of Dermatology

JF - Journal of Dermatology

IS - 12

ER -

Guidelines for the management of dermatomycosis (2019)

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this